- Supported exchanges /
- SHG /
- 688505.SHG
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505 SHG) stock market data APIs
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in phase I clinical trials for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Financial Data Overview
| 8.23 | |
| 8.18 | |
| - | |
| 8.26 | |
| 8.09 | |
| 6.0248-10.29 | |
| 6 581 M | |
| 74.8182 | |
| 703 M | |
| 692 M | |
| 0.0575 | |
| 0.0109 | |
| 0.21 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Fundamental Data is available in our Financial Data APIs
- Net Revenue 692 M
- EBITDA 72 046 K
- Earnings Per Share 0.11
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Earnings via APIs
- Latest Release 2023-08-10
- EPS/Forecast NaN
Get Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
